8%. 15%. 22.5%. 29%.

Four medications. One decade. Each generation reaches one more pathway than the last.

But that's just weight. Look at the rest of what changed when retatrutide activated all three signals at once.

Body composition

• 29% average weight loss.
• 76% improvement in joint pain.
• One in eight reported complete pain relief.

Cardiovascular

• A 14-point drop in blood pressure.
• A 27% drop in non-HDL, the harmful cholesterol.
• A 41% reduction in triglycerides.

Metabolic

• 86% average liver fat reduction.
• 93% saw liver fat return to normal.
• A 71% drop in fasting insulin.

Each generation adds one more pathway. GLP-1 quiets appetite. GIP works on fat tissue. Glucagon tells the liver to burn stored energy. The newer drugs reach further. Not just into hunger. Into blood pressure, cholesterol, joint pain, the liver itself.

Open questions remain. Why does the same dose produce different results in different people? Some lose 8 percent. Others lose 22 percent. What happens to the brain after years on these compounds? These questions drive the next decade of research.